CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 33 enrolled
Drug / intervention
Docosahexaenoic Acid (DHA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01563913
NCT01563913Phase 1Completed
CompareCT.gov

Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids

VA Office of Research and Development·interventional·Posted Mar 27, 2012·Updated Jun 29, 2018

In Brief

A Phase 1 clinical trial evaluating Docosahexaenoic Acid (DHA) and Placebo for Parkinson's Disease. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsOregon Health and Science University

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 27, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.3 years ago

Interventions

Docosahexaenoic Acid (DHA)drug

Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years

Placebodrug

Sugar Pill, taken for 1.5 years